共 57 条
[1]
Landis S.H., Murray T., Bolden S., Wingo P.A., Cancer statistics, 1999, CA Cancer J Clin, 49, pp. 8-31, (1999)
[2]
Young R.C., Walton L.A., Ellenberg S.S., Et al., Adjuvant therapy in stage I and II epithelial ovarian cancer. Results of two prospective randomized trials, N Engl J Med, 322, pp. 1021-1027, (1990)
[3]
Hoskins W.J., McGuire W.P., Brady M.F., Et al., The effect of diameter of largest residual disease on survival after primary cytoreductive surgery in patients with suboptimal residual epithelial ovarian carcinoma, Am J Obstet Gynecol, 170, pp. 974-979, (1994)
[4]
Bonnefoi H., A'Hern R.P., Fisher C., Et al., Natural history of stage IV epithelial ovarian cancer, J Clin Oncol, 17, pp. 767-775, (1999)
[5]
McGuire W.P., Hoskins W.J., Brady M.F., Et al., Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and stage IV ovarian cancer, N Engl J Med, 334, pp. 1-6, (1996)
[6]
Ford D., Easton D.F., Bishop D.T., Et al., Risk of cancer in BRCA1-mutation carriers, Lancet, 343, pp. 692-695, (1994)
[7]
Burke W., Daly M., Garber J., Et al., Recommendations for follow-up and care of individuals with inherited predisposition to cancer, II: BRCA1 and BRCA2. Cancer Genetics Studies Consortium, JAMA, 277, pp. 997-1003, (1997)
[8]
Ozols R.F., Morgan R.J., Copeland L., Et al., Update of the NCCN ovarian cancer practice guidelines, Oncology, 11, pp. 95-105, (1997)
[9]
McGowan L., Lesher L.P., Norris H.J., Barnett M., Mis-staging of ovarian cancer, Obstet Gynecol, 65, pp. 568-572, (1985)
[10]
van der Burg M.E.L., van Lent M., Buyse M., Et al., The effect of debulking surgery after induction chemotherapy on the prognosis in advanced epithelial ovarian cancer, N Engl J Med, 332, pp. 629-634, (1995)